During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
	$	3,265

As of December 31, 2024 the Company had fully paid the $3.3 million related to the reduction in workforce. This reduction in workforce was completed by June 30, 2024.

During the first quarter of 2024, the Company executed a reduction in workforce largely affecting its COVID-19 manufacturing workforce. The charges for termination benefits included in the Company's consolidated statement of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	231
Research and development	87
Sales and marketing	69
General and administrative	17
	$	404

As of December 31, 2024, the Company had fully paid the $0.4 million related to the reduction in workforce. This reduction in workforce was completed by December 31, 2024.

During the second quarter of 2024, the Company executed an additional reduction in workforce as the Company notified employees of its intention to consolidate its Novosanis site in Belgium into other locations by the end of December 31, 2024, discontinue the Diversigen molecular services line of business by the end of June 30, 2024, and consolidate facilities by bringing third-party manufacturing activities into its Pennsylvania facilities by the end of the third quarter of 2025. The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	889
Research and development	478
Sales and marketing	125
General and administrative	160
	$	1,652

As of December 31, 2025 the Company had $0.1 million accrued and had paid $1.5 million related to the reduction in workforce. No additional expenses were incurred during the year ended December 31, 2025. The Company expects this reduction in workforce to be completed by March 2026.

During the third quarter of 2024, the Company executed a reduction in workforce largely as the Company notified certain employees of its intention to discontinue its risk assessment business. Additional employees were notified in the fourth quarter of 2024. The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	246
Research and development	33
Sales and marketing	782
General and administrative	141
	$	1,202

As of December 31, 2025 the Company had $0.1 million accrued and had paid $1.1 million related to the reduction in workforce. No additional expense was incurred during the year ended December 31, 2025. The Company expects this reduction in workforce to be completed by September 2026.